Key facts
- It has raised $3.9M; the latest was Accelerator/Incubator in Dec 2024.
- Notable investors include Innovate UK, Creative Destruction Lab, Entrepreneurs First, University of Toronto, SyndicateRoom — 17 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 17 names
- ·Watchlist + deal alerts for Kuano
- ·The full record, as it builds
Funding rounds
No funding rounds for Kuano are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Kuano
Developer of a quantum mapping and AI-based discovery platform designed to offer assistance for drug discovery and design. The company's platform combines quantum physics, AI, and medicinal chemistry in a unique approach to transforming the discovery of therapeutics focused on enzyme inhibition, enabling drug developers to improve the quality of new drugs being produced, as well as reducing discovery time.
- Sector
- Healthcare
- HQ
- Cambridge, United Kingdom
- Founded
- 2020
- Employees
- 12
- Website
- kuano.ai/
- Ownership
- Privately Held (backing)
Kuano doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Kuano shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Kuano in its N-PORT filings yet. We sweep new filings monthly.